MI/25/11 – Postdoctoral Scientist – Leukaemia Biology group

Key Details

Job ID:
MI/25/11
Role:
Postdoctoral Scientist
Salary:
Salary in the range: £37,000 – £44,852 (dependent upon qualifications and experience)
Closing date:
31st March 2025

About the role

We are seeking to appoint a postdoctoral researcher who will continue and expand our work in the area of translational myeloid leukaemia epigenetics, therapeutics and gene regulation.

The programme of work will be focused on understanding how critical transcription factors involved in acute myeloid leukaemia recruit essential co-activators and/or co-repressors to chromatin and whether these recruitment domains can be targeted for therapeutic benefit, as has been the case, for example, with menin inhibition in AML.

About you

You should have a PhD in a biomedical discipline. A background in leukaemia research and/or chromatin & epigenetics is desirable but not essential.

Image of AML blast cells
Leukemia Biology cells image
High-resolution image of laboratory equipment and samples, used for scientific research and analysis.
Paterson Building Scientific Administration

More information

Background to role

Over the last decade the Leukaemia Biology laboratory at the Cancer Research UK Manchester Institute has delivered a successful programme of bench-to-bedside translational research in myeloid blood cancer, with significant impacts in other haematological cancers such as myeloma and lymphoma. Our focus has been on understanding the basic biology of transcription factors, their co-activators and co-repressors. With this knowledge we have then collaborated with colleagues in medicinal chemistry and in the pharmaceutical industry to drug these targets and bring them through a succession of clinical trials with patient benefit being the longer-term goal. Some key examples of this include our work on LSD1 and more recently our work with a bromodomain inhibitor of the histone acetyltransferases EP300/CBP.
Building on these and other recent successes, the appointed postdoctoral researcher will continue and expand our work in the area of translational myeloid leukaemia epigenetics, therapeutics and gene regulation.

About you

You should have a PhD in a biomedical discipline. A background in leukaemia research and/or chromatin & epigenetics is desirable but not essential.

You should have a strong track record of past accomplishments, with wet lab experimental skills and excellent writing skills. Significant experience in ChIP sequencing and/or mass spectrometry would be advantageous together with good experience in analysis of the arising datasets, although this post will be supported by colleagues within our core bioinformatics facility. Experience with in vivo work would also be a benefit. To acquaint yourself with the range of experimental techniques and approaches in our laboratory, please read our recent publications (search for Tim Somervaille in our Publications page).

Group Leader Tim Somervaille

Professor Tim Somervaille is a Clinician Scientist at the Cancer Research UK Manchester Institute where he leads the Leukaemia Biology Laboratory. His scientific and clinical research interest is in myeloid cancer, including acute myeloid leukaemia and the myeloproliferative disorders.

The Leukaemia Biology group

The goal of the Leukaemia Biology group is to develop understanding of disease mechanisms in myeloid lineage blood cancers and through doing so to identify candidate therapeutic targets for development through to the clinic.

About CRUK Manchester Institute

Our aim is to understand the fundamental basis of cancer and apply that knowledge to developing new treatment strategies for cancer patients. Our advanced research programmes span a spectrum of cancer research, from the molecular and cellular basis of cancer through to drug discovery, translational research and clinical trials.
The Institute has access to outstanding laboratory facilities and exceptional core services, including next generation sequencing, microarrays, confocal microscopy, bioinformatics, histology and mass-spectrometry.

Background to role
About you
Group Leader Tim Somervaille
The Leukaemia Biology group
About CRUK Manchester Institute

How to apply?

To apply for this position please complete the online application through our secure online portal, JobMarker, which you can access by clicking the “Apply Now” button.

Please ensure you detail the names of three referees and ensure you submit your application before 11:59pm on the closing date.

Closing date: 31 March 2025

For any informal enquiries about this post, please use this form to contact Tim Somervaille

Please enable JavaScript in your browser to complete this form.

Why choose Cancer Research UK Manchester Institute?

The Cancer Research UK Manchester Institute, an Institute of The University of Manchester, is a world-leading centre for excellence in cancer research. The Institute is core funded by Cancer Research UK (www.cancerresearchuk.org),
the largest independent cancer research organisation in the world.

We are partnered with The Christie NHS Foundation Trust, one of the largest cancer treatment centres in Europe, which is located adjacent to the CRUK MI Manchester Institute in South Manchester. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes.

Careers that have a lasting impact on cancer research and patient care

We are always on the lookout for talented and motivated people to join us.  Whether your background is in biological or chemical sciences, mathematics or finance, computer science or logistics, use the links below to see roles across the Institute in our core facilities, operations teams, research groups, and studentships within our exceptional graduate programme.

Gloved hands filling a stripette white lab coat

Latest from CRUK MI

Cancer Research In the Paterson Building

Find out more about the facilities across the Institute

Leukaemia Immunology & Transplantation

The Leukaemia Immunology and Transplantation laboratory aim to develop a comprehensive strategy to prevent post-transplant relapse in patients treated with allogeneic haematopoietic stem cell transplantation – the only curative therapy for many patients with acute myeloid leukaemia (AML) and other poor-risk haematological malignancies.

Patient derived preclinical models reveal novel biology of SCLC

Immune detection of dying tumour cells can elicit cancer immunity when the host permits it

Cancer Research In the Paterson Building
Leukaemia Immunology & Transplantation
Patient derived preclinical models reveal novel biology of SCLC